Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should clinical pharmacokinetic bridging studies between Caucasian and Asian populations be required for approval of monoclonal antibodies?

× No keyword cloud information.

9 in total

1. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects.

Authors: Mary Morrison; Guiseppe Palermo; Christophe Schmitt
Journal: Eur J Clin Pharmacol Date: 2015-09-12 Impact factor: 2.953

2. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.

Authors: Gerald R Galluppi; Nicolas Wisniacki; Chris Stebbins
Journal: Br J Clin Pharmacol Date: 2016-04-08 Impact factor: 4.335

Review 3. Clinical Development and Regulatory Pathways of Monoclonal Antibodies in Japan.

Authors: Hua Liao; Zhaoyang Li
Journal: Ther Innov Regul Sci Date: 2021-11-25 Impact factor: 1.778

4. Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors: Colby S Shemesh; Phyllis Chan; Hui Shao; Derek-Zhen Xu; Daniel Combs; Shweta Vadhavkar; René Bruno; Benjamin Wu
Journal: Liver Cancer Date: 2021-06-10 Impact factor: 11.740

5. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations.

Authors: Chen Wang; Qingshan Zheng; Mingqiang Zhang; Hong Lu
Journal: Br J Clin Pharmacol Date: 2018-10-17 Impact factor: 4.335

6. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.

Authors: Yanli Zhuang; Sally Lyn; Yuan Lv; Zhenhua Xu; Esther Bouman-Thio; Tara Masterson; Joyce A Ford; Monica Keen; Kevin J Petty; Hugh M Davis; Honghui Zhou
Journal: Clin Drug Investig Date: 2013-11 Impact factor: 2.859

7. Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?

Authors: Masaru Hirano; Masanori Yamada; Toshiaki Tanaka; Toshiko Koue; Tomohisa Saito; Mitsuo Higashimori; Hisao Ochiai; Junichi Yamamoto; Saori Yaguchi; Sachiko Mita; Katsutoshi Hara
Journal: Clin Pharmacol Drug Dev Date: 2021-11-26

8. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

Authors: John Zhai; Yan Qin; Jun Zhu; Yuqin Song; Zhixiang Shen; Xin Du; Candice Jamois; Michael Brewster; Yuankai Shi; Jun Shi
Journal: Br J Clin Pharmacol Date: 2017-02-14 Impact factor: 4.335

Review 9. Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors: Veena A Thomas; Joseph P Balthasar
Journal: Antibodies (Basel) Date: 2019-12-04

9 in total